Top-News

Iovance Biotherapeutics Aktie News

Aktie
WKN:  A2DT49 ISIN:  US4622601007 US-Symbol:  IOVA Branche:  Biotechnologie Land:  USA
1,8774 €
-0,0076 €
-0,40%
12:01:10 Uhr
Depot/Watchlist
Marktkapitalisierung *
709,73 Mio. €
Streubesitz
36,98%
KGV
-6,07
Index-Zuordnung
-

Iovance Biotherapeutics News

15.10.25 - PR Newswire
Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge PR Newswire
15.10.25 - PR Newswire
Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge PR Newswire
17.09.25 - PR Newswire
Advancing Cancer Research Brings New Hope for Patients Worldwide
Advancing Cancer Research Brings New Hope for Patients Worldwide PR Newswire
17.09.25 - PR Newswire
Advancing Cancer Research Brings New Hope for Patients Worldwide
Advancing Cancer Research Brings New Hope for Patients Worldwide PR Newswire
14.08.25 - PR Newswire
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment PR Newswire
14.07.25 - PR Newswire
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV PR Newswire
14.07.25 - PR Newswire
Lost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
Lost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm PR Newswire
14.07.25 - PR Newswire
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
13.07.25 - PR Newswire
IOVA Deadline: IOVA Investors with Losses in Excess of $100K Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
IOVA Deadline: IOVA Investors with Losses in Excess of $100K Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit PR Newswire
12.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ...
11.07.25 - PR Newswire
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
11.07.25 - PR Newswire
July 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against IOVA
July 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against IOVA PR Newswire
10.07.25 - PR Newswire
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
10.07.25 - PR Newswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Iovance Biotherapeutics, Inc.(IOVA) Shareholders
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Iovance Biotherapeutics, Inc.(IOVA) Shareholders PR Newswire
08.07.25 - PR Newswire
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
08.07.25 - PR Newswire
IOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
IOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP PR Newswire
08.07.25 - PR Newswire
Levi & Korsinsky Notifies Shareholders of Iovance Biotherapeutics, Inc.(IOVA) of a Class Action Lawsuit and an Upcoming Deadline
Levi & Korsinsky Notifies Shareholders of Iovance Biotherapeutics, Inc.(IOVA) of a Class Action Lawsuit and an Upcoming Deadline PR Newswire
07.07.25 - PR Newswire
IOVA Deadline: IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
IOVA Deadline: IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit PR Newswire
07.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ...
07.07.25 - PR Newswire
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +0,36%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »